Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
Abstract: Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.
- Weitere Titel
-
Segurança na mudança direta de natalizumabe para fingolimode em um grupo de pacientes com esclerose múltipla e positivos para JCV
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis ; volume:74 ; number:08 ; year:2016 ; pages:650-652
Arquivos de neuro-psiquiatria ; 74, Heft 08 (2016), 650-652
- Beteiligte Personen und Organisationen
-
Fragoso, Yara Dadalti
Alves-Leon, Soniza Vieira
Becker, Jefferson
Brooks, Joseph Bruno Bidin
Correa, Eber Castro
Damasceno, Alfredo
Gama, Paulo Diniz da
Gama, Rodrigo Assad da
Matta, Andre Palma da Cunha
Maciel, Ernane Pires
Cristina d’Avila Winckler, Thereza
- DOI
-
10.1590/0004-282X20160090
- URN
-
urn:nbn:de:101:1-2023101912332969449654
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fragoso, Yara Dadalti
- Alves-Leon, Soniza Vieira
- Becker, Jefferson
- Brooks, Joseph Bruno Bidin
- Correa, Eber Castro
- Damasceno, Alfredo
- Gama, Paulo Diniz da
- Gama, Rodrigo Assad da
- Matta, Andre Palma da Cunha
- Maciel, Ernane Pires
- Cristina d’Avila Winckler, Thereza
Ähnliche Objekte (12)
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod Therapy for Multiple Sclerosis
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod Therapy for Multiple Sclerosis
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod Therapy for Multiple Sclerosis
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy